Physician profile
Eric Edward Conologue
NPI 1316484702
$4,286.18
in general payments reported to CMS, 2019-2025
28 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $925 · 2023: $738 · 2024: $723 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.36 |
| Education | $128.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $620.66 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $588.43 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $472.18 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $334.58 | 2021-2025 | |
| Amgen INC. | $300.17 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $258.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.80 | 2021-2025 | Takhzyro, Eohilia, Hyqvia |
| Abbvie INC. | $206.05 | 2022-2025 | |
| Glaxosmithkline, LLC. | $198.48 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Organon LLC | $123.33 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $110.70 | 2021-2023 | Orladeyo |
| Optinose US, INC. | $109.78 | 2021-2025 | |
| Genentech USA, INC. | $109.54 | 2024 | Xolair |
| Pharming Healthcare, INC. | $82.45 | 2022-2025 | Ruconest |
| Pfizer INC. | $72.43 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $71.45 | 2021-2022 | |
| Grifols USA, LLC | $64.72 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Covis Pharma Gmbh | $53.13 | 2021-2022 | |
| Alk-Abello, INC | $47.69 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $35.97 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $32.03 | 2025 | Dawnzera |
| Kaleo, INC. | $30.26 | 2022-2023 | Auvi-Q |
| Blueprint Medicines Corporation | $21.96 | 2023 | Ayvakit |
| Phadia US INC. | $21.29 | 2021 | |
| Merck Sharp & Dohme LLC | $17.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2023 | Spiriva |
| Uswm, LLC | $16.00 | 2021 | |
| Hikma Pharmaceuticals USA | $13.92 | 2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Conologue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.